ResMed's CEO Discusses Q3 2012 Results - Earnings Call Transcript

ResMed (RMD)

Q3 2012 Earnings Call

April 26, 2012 4:30 pm ET


Peter C. Farrell - Founder, Executive Chairman, Chief Executive Officer and President

Brett A. Sandercock - Chief Financial Officer and Principal Accounting Officer

Unknown Executive -

Michael J. Farrell - President of Americas Operations

Geoff Neilson - President of Respiratory Care Strategic Business Unit

Robert Douglas - Chief Operating Officer


David Low - Deutsche Bank AG, Research Division

Ben Andrew - William Blair & Company L.L.C., Research Division

Matthew Prior - BofA Merrill Lynch, Research Division

Joanne K. Wuensch - BMO Capital Markets U.S.

David C. Clair - Piper Jaffray Companies, Research Division

Saul Hadassin - Crédit Suisse AG, Research Division

David Stanton - Nomura Securities Co. Ltd., Research Division

Steven D. Wheen - JP Morgan Chase & Co, Research Division

Ben C. Haynor - Feltl and Company, Inc., Research Division

Michael Matson - Mizuho Securities USA Inc., Research Division



Good day, ladies and gentlemen, and welcome to the Third Quarter 2012 ResMed Incorporated Earnings Conference Call. My name is Angela, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.

The company has asked me to read -- address certain matters. First, ResMed does not authorize the recording of any portion of this conference call for any purpose. Second, during the conference call, ResMed may make forward-looking statements such as: Projections of future revenue or earnings, new product development or new markets for the company's products. These statements are made under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Risks and uncertainties exist that could cause actual results to materially differ from the forward-looking statements.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates